Celcuity (CELC) stock was up more than 113% pre-bell Monday after the company said results from a phase 3 trial showed that a combination of gedatolisib, palbociclib, and fulvestrant reduced the risk of disease progression or death by 76% compared with fulvestrant alone in patients with locally advanced or metastatic breast cancer.
Mill City Ventures III (MCVT) shares were 61% higher, extending Friday's rally.
TruGolf (TRUG) stock was up 22% following a 5.8% loss on Friday.
22nd Century Group (XXII) shares were 23% higher, adding to a 4.1% increase in the previous session.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。